Camber Pharmaceuticals issues nationwide recall of atovaquone due to possible microbial contamination

Camber Pharmaceuticals, Inc., based in Piscataway, NJ, is voluntarily recalling lot # E220182 of Atovaquone Oral Suspension, USP 750 mg/5 mL due to potential Bacillus cereus contamination. In high-risk immunocompromised patients, such microbial contamination could result in disseminated, life-threatening infections such as endocarditis and necrotizing soft tissue infections.